Bone drugs may double as liver fat fighters — a trial puts them to the test
NCT ID NCT05493761
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This trial investigates whether two common osteoporosis medications, denosumab and alendronate, can reduce liver fat and scarring in postmenopausal women who also have nonalcoholic fatty liver disease (NAFLD). The study will compare changes in liver fat and stiffness over 12 months in women receiving either drug. If denosumab proves effective, it could offer a new treatment avenue for NAFLD, a condition with no approved medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- denosumab or alendronate (anti-osteoporosis medications)
- What this could lead to
- If denosumab reduces liver fat and fibrosis, it could point toward a new use for an existing osteoporosis drug in treating NAFLD.
- What could go wrong
- This is a small, non-randomized study, so results may not be conclusive. Denosumab can cause side effects like bone or joint pain, and its effect on the liver is still uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki
Thessaloniki, 56403, Greece
-
424 General Military Hospital
Thessaloniki, 56429, Greece
-
Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki
Thessaloniki, 54642, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Follow-Up drug keep bones strong after initial osteoporosis therapy?
- Can a single infusion lock in bone gains after osteoporosis treatment?
- Could common statins be a surprise weapon against brittle bones?
- Blood donation may improve diabetes and fatty liver, study finds
- Could adding a second drug boost bone strength in osteoporosis?
- Can a phone app beat fatty liver? new trial tests digital coaching